title: Nedocromil in the outpatient management of asthma.
abstract: OBJECTIVE
  To more closely approximate the use of a nonsteroidal inhaled anti-inflammatory medication for asthma, nedocromil sodium, under actual ambulatory practice conditions.
  
  
  METHODS
  Large, open-label trial.
  
  
  METHODS
  One thousand two hundred one patients from 286 primary care and specialty centers.
  
  
  METHODS
  Four weeks of treatment with nedocromil sodium (4 mg delivered from the valve and 3.5 mg delivered from the mouthpiece of a metered inhalor [2 puffs, four times daily]).
  
  
  METHODS
  Asthma symptom scores, peak expiratory flow rate, a lifestyle assessment measures questionnaire, and mean number of days missed per month from work or school.
  
  
  RESULTS
  Statistically significant improvements were seen after 1 and 4 weeks of treatment for cough, daytime and nighttime asthma, morning tightness, peak expiratory flow rate, and all four measured lifestyle assessment factors (P < .001). An additional clinically relevant outcome measure, mean number of days missed per month from work or school, was reduced by 75% (P < .001). No serious adverse reactions were reported.
  
  
  CONCLUSIONS
  This study reproduces the high level of efficacy and safety of nedocromil that was previously reported in placebo-controlled clinical studies.
authors.affiliation: University of Minnesota, Minneapolis, USA.
authors.forename: J M
authors.initials: JM
authors.lastname: Keenan
authors.forename: L
authors.initials: L
authors.lastname: Bielory
authors.forename: P C
authors.initials: PC
authors.lastname: Flamion
authors.forename: L B
authors.initials: LB
authors.lastname: Ford
authors.forename: M
authors.initials: M
authors.lastname: Murcek
authors.forename: D R
authors.initials: DR
authors.lastname: Pyszczynski
authors.forename: J
authors.initials: J
authors.lastname: Selcow
authors.forename: A
authors.initials: A
authors.lastname: Silvagni
authors.forename: M
authors.initials: M
authors.lastname: Tarpay
authors.forename: M J
authors.initials: MJ
authors.lastname: Zitt
mesh_terms: D000280:Administration, Inhalation; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000553:Ambulatory Care; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D002648:Child; D005260:Female; D006801:Humans; D008019:Life Style; D008297:Male; D008875:Middle Aged; D017835:Nedocromil / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010366:Peak Expiratory Flow Rate; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D018927:Anti-Asthmatic Agents; D017835:Nedocromil